Enterprise Value

49.25M

Cash

27.15M

Avg Qtr Burn

-5.984M

Short % of Float

4.06%

Insider Ownership

3.89%

Institutional Own.

39.96%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Soquelitinib (CPI-818) (ITK inhibitor) Details
Lymphoma, Cutaneous T cell lymphoma, Cancer, Blood cancer

Phase 3

Initiation

Mupadolimab (CPI-006) (Anti-CD73) Details
Lung cancer, Renal cell carcinoma, Cancer, Non-small cell lung carcinoma

Phase 2

Update

Phase 2

Initiation

Phase 1/2

Data readout

Mupadolimab + pembrolizumab Details
Head and neck cancer, Cancer, Non-small cell lung carcinoma

Phase 1b

Update

Soquelitinib (CPI-818) (ITK inhibitor) Details
Atopic dermatitis, Skin disease/disorder

Phase 1

Data readout

Failed

Discontinued